Abstract
Aim: To perform a genetic screening for the multiple endocrine neoplasia type 1 (MEN1) gene mutations in patients affected by an apparently sporadic form of the disease, referred to an internal medicine unit of a large general hospital. Subjects and methods: In a group of 12 consecutive patients presenting clinical features of MEN type 1 syndrome, we performed a genetic screening for germline MEN1 gene mutations, including complete sequencing of the coding region (exons 2 to 10) and multiplex ligation-dependent probe amplification analysis for large deletion detection. Results: Among these patients affected by apparently sporadic MEN type 1 syndrome, a targeted clinical history could detect indirect support for a diagnosis of familial condition only in 2 cases. The genetic screening identified pathogenic germline MEN1 gene mutations in 3 patients (25%). A previously unknown 18 base-pair deletion within exon 3, c.564_581 delCAATGGGGAGCAGACAGC, resulting in loss of 6 amino acids (pAsp189_Ala194del), was found in heterozygosis in a woman affected by primary hyperparathyroidism and multifocal pancreatic neoplasia. Conclusions: Our results underscore the importance of performing genetic testing also in apparently sporadic MEN1 patients and extend the list of molecular variants leading to inactivation of the MEN1 gene.
Similar content being viewed by others
References
Lemos MC, Thakker RV. Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. Hum Mutat 2008, 29: 22–32.
Cebrián A, Ruiz-Llorente S, Cascón A, et al. Mutational and gross deletion study of the MEN1 gene and correlation with clinical features in Spanish patients. J Med Genet 2003, 40: e72.
Pannett AA, Thakker RV. Multiple endocrine neoplasia type 1. Endocr Rel Canc 1999, 6: 449–73.
Kouvaraki MA, Lee JE, Shapiro SE, et al. Genotype-phenotype analysis in multiple endocrine neoplasia type 1. Arch Surg 2002, 137: 641–7.
Trump D, Farren B, Wooding C, et al. Clinical studies of multiple endocrine neoplasia type 1 (MEN1). QJM 1996, 89: 653–69.
Marx S, Spiegel AM, Skarulis MC, Doppman JL, Collins FS, Liotta LA. Multiple endocrine neoplasia type 1: clinical and genetic topics. Ann Intern Med 1998, 129: 484–94.
Bassett JH, Forbes SA, Pannett AA, et al. Characterization of mutations in patients with multiple endocrine neoplasia type 1. Am J Hum Genet 1998, 62: 232–44.
Doherty GM, Olson JA, Frisella MM, Lairmore TC, Wells SA Jr, Norton JA. Lethality of multiple endocrine neoplasia type I. World JSurg 1998, 22: 581–6.
Brandi ML, Gagel RF, Angeli A, et al. Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2. J Clin Endocrinol Metab 2001, 86: 5658–71.
Lemos MC, Thakker RV. Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. Hum Mutat 2008, 29: 22–32.
Chandrasekharappa SC, Teh BT. Functional studies of the MEN1 gene. J Intern Med 2003, 253: 603–15.
Poisson A, Zablewska B, Gaudray P. Menin interacting proteins as clues toward the understanding of multiple endocrine neoplasia type 1. Cancer Lett 2003, 189: 1–10.
Balogh K, Patócs A, Hunyady L, Rácz K. Menin dynamics and functional insight: take your partners. Mol Cell Endocrinol 2010, 326: 80–4.
Agarwal SK, Novotny EA, Crabtree JS, et al. Transcription factor JunD, deprived of menin, switches from growth suppressor to growth promoter. Proc Natl Acad Sci 2003, 100: 10770–5.
Gracanin A, Dreijerink KM, van der Luijt RB, Lips CJ, Höppener JW. Tissue selectivity in multiple endocrine neoplasia type 1-associated tumorigenesis. Cancer Res 2009, 69: 6371–4.
Guo SS, Sawicki M P. Molecular and genetic mechanisms of tumorigenesis in multiple endocrine neoplasia type 1. Mol Endocrinol 2001, 15: 1653–64.
Bosman F, Carneiro F, Hruban R, et al. WHO Classifcation of tumors of the digestive system. Lyon: IARC Press, 2010.
Schmidt MC, Henke RT, Stangl AP, et al. Analysis of the MEN1 gene in sporadic piytuitary adenomas. J Pathol 1999, 188: 168–73.
Chandrasekharappa SC, Guru SC, Manickam P, et al. Positional cloning of the gene for multiple endocrine neoplasia type 1. Science 1997, 276: 404–7.
Ferolla P, Falchetti A, Filosso P, et al. Thymic neuroendocrine carcinoma (carcinoid) in multiple endocrine neoplasia type 1 syndrome: the Italian series. J Clin Endocrinol Metab 2005, 90: 2603–9.
Falchetti A, Marini F, Luzi E et al. Multiple endocrine neoplasia type 1 (MEN1): not only inherited endocrine tumors. Genet Med 2009, 11: 825–35.
Marinoni I, Pellegata NS. p27kip1: a new multiple endocrine neoplasia gene? Neuroendocrinology 2011, 93: 19–28.
Georgitsi M. MEN-4 and other multiple endocrine neoplasias due to cyclin-dependent kinase inhibitors (p27(Kip1) and p18(INK4C)) mutations. Best Pract Res Clin Endocrinol Metab 2010, 24: 425–37.
Georgitsi M, Raitila A, Karhu A, et al. Germline CDKN1 B/p27Kip1 mutation in multiple endocrine neoplasia. J Clin Endocrinol Metab 2007, 92: 3321–5.
Stratakis CA, Tichomirowa MA, Boikos S, et al. The role of germline AIP, MEN1, PRKAR1A, CDKN1B and CDKN2C mutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes. Clin Genet 2010, 78: 457–63.
Klein RD, Salih S, Bessoni J, Bale AE. Clinical testing for multiple endocrine neoplasia type 1 in a DNA diagnostic laboratory. Genet Med 2005, 7: 131–8.
Wautot V, Vercherat C, Lespinasse J, et al. Germline mutation profile of MEN1 in multiple endocrine neoplasia type 1: search for correlation between phenotype and the functional domains of the MEN1 protein. Hum Mutat 2002, 20: 35–47.
The Universal Mutation Database. The MEN1 mutations database. http://www.umd.be/MEN1/
Kassem M, Kruse TA, Wong FK, Larsson C, Teh BT. Familial isolated hyperparathyroidism as a variant of multiple endocrine neoplasia type 1 in a large Danish pedigree. J Clin Endocrinol Metab 2000, 85: 165–7.
Teh BT, Farnebo F, Twigg S, et al. Familial isolated hyperparathyroidism maps to the hyperparathyroidism-jaw tumor locus in 1q21–q32 in a subset of families. J Clin Endocrinol Metab 1998, 83: 2114–20.
Fujimori M, Shirahama S, Sakurai A, et al. Novel V184E MEN1 germline mutation in a Japanese kindred with familial hyperparathyroidism. Am J Med Genet 1998, 80: 221–2.
Belar O, De la Hoz C, Pérez-Nanclares G, Castaño L, Gaztambide S; Spanish MEN1 Group. Novel mutations In MEN1, CDKN1b and AIP genes in patients with multiple endocrine neoplasia type 1 syndrome in Spain. Clin Endocrinol 2011, Oct 25 [Epub ahead of print]; doi: 10.1111/j.1365-2265.2011.04269.x
Hou R, Manwaring LP, Moley JF, Whelan A. A novel missense mutation in the MEN1 gene in a patient with multiple endocrine neoplasia type 1. Endocr Pract 2011, 17: e63–7.
Raef H, Zou M, Baitei EY, et al. A novel deletion of the MEN1 gene in a large family of multiple endocrine neoplasia type 1 (MEN1) with aggressive phenotype. Clin Endocrinol 2011, 75: 791–800.
American Society of Clinical Oncology. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol 2003, 21: 2397–406.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Giacché, M., Panarotto, A., Mori, L. et al. A novel menin gene deletional mutation in a little series of Italian patients affected by apparently sporadic multiple endocrine neoplasia type 1 syndrome. J Endocrinol Invest 35, 124–128 (2012). https://doi.org/10.1007/BF03345419
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03345419